First Targeted RAS Inhibitor Approved for Pancreatic Cancer

FDA approved daraxonrasib, the first targeted RAS inhibitor for metastatic pancreatic cancer, with median overall survival of 13.2 versus 6.7 months compared with chemotherapy and better quality-of-life outcomes. Earlier-line trials, resistance, molecular testing, durability, and cost will determine its broader impact.